Reported Sunday, Disc Medicine Shares Phase 1b Results For DISC-0974 In Myelofibrosis Patients At ASH 2024, Starts Phase 2 Trial
Reported Sunday, Disc Medicine Shares Phase 1b Results For DISC-0974 In Myelofibrosis Patients At ASH 2024, Starts Phase 2 Trial
報告顯示,Disc Medicine在ASH 2024公佈了DISC-0974在骨髓纖維化患者中的10億階段試驗結果,並啓動了第2階段試驗。
- Demonstrated durable hematologic response across all patient subgroups, regardless of baseline transfusion status and concomitant JAK inhibitor therapy
- Phase 2 study in MF anemia has been initiated, enrolling a broad range of patient types
- 在所有患者亞組中展示了持久的血液學反應,無論基線輸血狀態和共用JAk抑制劑治療如何。
- 已啓動MF貧血的第2期研究,招募了廣泛範圍的患者類型。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。